Fontolizumab

From Self-sufficiency
Jump to: navigation, search
Fontolizumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target interferon gamma
Identifiers
CAS Number 326859-36-3
ATC code none
Chemical data
Molar mass ca. 150 kDa
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]

References

  1. Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
  2. Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B; Riff, D (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases: NA. doi:10.1002/ibd.21038. PMID 19637334. 
  3. ClinicalTrials.gov NCT00281294 A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis